Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 29.04.2019 2 AJR Am J Roentgenol 3 BJU Int 2 BMC Cancer 1 BMC Urol 2 Br J Radiol 1 Cancer 1 Cancer Lett 1 Eur J Radiol 1 Eur Urol 1 Int J Cancer 1 J Clin Oncol 3 J Urol 1 Magn Reson Imaging 4 Prostate

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. COSTA DN, Passoni NM, Leyendecker JR, de Leon AD, et al
   Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI.
   AJR Am J Roentgenol. 2018 Feb 28:1-7. doi: 10.2214/AJR.17.18849.
   PubMed     Text format     Abstract available
   
   
2. SHERIDAN AD, Nath SK, Aneja S, Syed JS, et al
   MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
   AJR Am J Roentgenol. 2018 Feb 28:W1-W8. doi: 10.2214/AJR.17.18680.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

3. REICHARD CA, Hoffman KE, Tang C, Williams SB, et al
   Radical Prostatectomy or Radiotherapy for High and Very High Risk Prostate Cancer: A Multidisciplinary Clinic Experience of Patients Eligible for Either Treatment.
   BJU Int. 2019 Apr 22. doi: 10.1111/bju.14780.
   PubMed     Text format     Abstract available
   
   
4. VILLUMSEN BR, Jorgensen MG, Frystyk J, Hordam B, et al
   Home-based exergaming was safe and significantly improved 6-min walking distance in prostate cancer patients: a single-blinded randomized controlled trial.
   BJU Int. 2019 Apr 22. doi: 10.1111/bju.14782.
   PubMed     Text format     Abstract available
   
   
5. RANASINGHE WKB, Williams S, Ischia J, Wetherell D, et al
   Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
   BJU Int. 2019 Apr 23. doi: 10.1111/bju.14709.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

6. DULSKAS A, Cereska V, Zurauskas E, Stratilatovas E, et al
   Prostate cancer solitary metastasis to anal canal: case report and review of literature.
   BMC Cancer. 2019;19:374.
   PubMed     Text format     Abstract available
   
   
7. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
   Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme.
   BMC Cancer. 2019;19:368.
   PubMed     Text format     Abstract available
   
   

   
   BMC Urol

8. WANG JH, Sierra P, Richards KA, Abel EJ, et al
   Impact of bilateral biopsy-detected prostate cancer on an active surveillance population.
   BMC Urol. 2019;19:26.
   PubMed     Text format     Abstract available
   
   

   
   Br J Radiol

9. WANG T, Press RH, Giles M, Jani AB, et al
   Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
   Br J Radiol. 2019 Mar 26:20190089. doi: 10.1259/bjr.20190089.
   PubMed     Text format     Abstract available
   
   
10. TAMPONI M, Gabriele D, Maggio A, Stasi M, et al
    Prostate cancer dose-response, fractionation sensitivity and repopulation parameters evaluation from 25 international radiotherapy outcome data sets.
    Br J Radiol. 2019 Apr 24:20180823. doi: 10.1259/bjr.20180823.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

11. TAGAWA ST, Vallabhajosula S, Christos PJ, Jhanwar YS, et al
    Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32072.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

12. CHEN X, Shi H, Bi X, Li Y, et al
    Targeting the Deubiquitinase STAMBPL1 Triggers Apoptosis in Prostate Cancer Cells by Promoting XIAP Degradation.
    Cancer Lett. 2019 Apr 17. pii: S0304-3835(19)30251.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Radiol

13. HERMIE I, Van Besien J, De Visschere P, Lumen N, et al
    Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Eur J Radiol. 2019;114:92-98.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

14. FRASER M
    Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Apr 19. pii: S0302-2838(19)30284.
    PubMed     Text format    
    
    

    
    Int J Cancer

15. WANG R, Chu GC, Wang X, Wu JB, et al
    Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32370.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

16. DOWNER MK, Kenfield SA, Stampfer MJ, Wilson KM, et al
    Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2019 Apr 26:JCO1802462. doi: 10.1200/JCO.18.02462.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

17. HAESE A, Trooskens G, Steyaert S, Hessels D, et al
    Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
    J Urol. 2019 Apr 26:101097JU0000000000000293. doi: 10.1097/JU.0000000000000293.
    PubMed     Text format     Abstract available
    
    
18. JOHNSON DC, Kwok E, Ahn C, Pashchinskiy A, et al
    Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model.
    J Urol. 2019 Apr 22:101097JU0000000000000283. doi: 10.1097/JU.0000000000000283.
    PubMed     Text format     Abstract available
    
    
19. DASKIVICH TJ, Thomas IC, Luu M, Shelton JB, et al
    External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Apr 22:101097JU0000000000000287. doi: 10.1097/JU.0000000000000287.
    PubMed     Text format     Abstract available
    
    

    
    Magn Reson Imaging

20. ZIAYEE F, Muller-Lutz A, Gross J, Quentin M, et al
    Influence of arterial input function (AIF) on quantitative prostate dynamic contrast-enhanced (DCE) MRI and zonal prostate anatomy.
    Magn Reson Imaging. 2018 Jun 11. pii: S0730-725X(18)30212.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

21. MOLL JM, Kumagai J, van Royen ME, Teubel WJ, et al
    A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23799.
    PubMed     Text format     Abstract available
    
    
22. XIANG P, Jin S, Yang Y, Sheng J, et al
    Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23810.
    PubMed     Text format     Abstract available
    
    
23. DUIJVESZ D, Rodriguez-Blanco G, Hoogland AM, Verhoef EI, et al
    Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer.
    Prostate. 2019 Apr 24. doi: 10.1002/pros.23813.
    PubMed     Text format     Abstract available
    
    
24. YILMAZ B, Turkay R, Colakoglu Y, Baytekin HF, et al
    Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Prostate. 2019 Apr 23. doi: 10.1002/pros.23812.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: